Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 120Recruiting 36Terminated 33Unknown 28Active not recruiting 11Withdrawn 10Not yet recruiting 7Suspended 1No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Pancreatic Neoplasms 17Stomach Neoplasms 13Carcinoma, Hepatocellular 13Breast Neoplasms 8Rectal Neoplasms 7Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Cholangiocarcinoma 4Neoplasm Metastasis 3Lung Neoplasms 3Endometrial Neoplasms 3Diabetes Mellitus 3Crohn Disease 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Multiple Sclerosis 2Multiple Myeloma 2Melanoma 2Liver Neoplasms 2Irritable Bowel Syndrome 2Head and Neck Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2

Interventions

Anticoagulants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Adenocarcinoma × Gastrointestinal × Clear all
NCT00443573 2008-05-07

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

ARCA Biopharma, Inc.

Phase 1/2 Suspended
100 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡